JP3987104B2 - シャペロニン１０のアンタゴニスト - Google Patents

シャペロニン１０のアンタゴニスト Download PDF

Info

Publication number
JP3987104B2
JP3987104B2 JP51529695A JP51529695A JP3987104B2 JP 3987104 B2 JP3987104 B2 JP 3987104B2 JP 51529695 A JP51529695 A JP 51529695A JP 51529695 A JP51529695 A JP 51529695A JP 3987104 B2 JP3987104 B2 JP 3987104B2
Authority
JP
Japan
Prior art keywords
cpn10
epf
antibody
cells
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51529695A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09505811A (ja
Inventor
モートン、ハレ
キャバナフ、アリス・クリスチナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland
Original Assignee
University of Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM8234A external-priority patent/AUPM823494A0/en
Application filed by University of Queensland filed Critical University of Queensland
Publication of JPH09505811A publication Critical patent/JPH09505811A/ja
Application granted granted Critical
Publication of JP3987104B2 publication Critical patent/JP3987104B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
JP51529695A 1993-11-30 1994-11-30 シャペロニン１０のアンタゴニスト Expired - Fee Related JP3987104B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPM270593 1993-11-30
AUPM8234A AUPM823494A0 (en) 1994-09-16 1994-09-16 Diagnostic and therapeutic uses of chaperonin 10
AU8234 1994-09-16
PCT/AU1994/000742 WO1995015339A1 (en) 1993-11-30 1994-11-30 Antagonists to chaperonin 10
AU2705 1999-09-08

Publications (2)

Publication Number Publication Date
JPH09505811A JPH09505811A (ja) 1997-06-10
JP3987104B2 true JP3987104B2 (ja) 2007-10-03

Family

ID=25644587

Family Applications (3)

Application Number Title Priority Date Filing Date
JP51529695A Expired - Fee Related JP3987104B2 (ja) 1993-11-30 1994-11-30 シャペロニン１０のアンタゴニスト
JP51529495A Expired - Fee Related JP3545408B2 (ja) 1993-11-30 1994-11-30 シャペロニン１０
JP2003319869A Expired - Fee Related JP3986481B2 (ja) 1993-11-30 2003-09-11 シャペロニン１０

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP51529495A Expired - Fee Related JP3545408B2 (ja) 1993-11-30 1994-11-30 シャペロニン１０
JP2003319869A Expired - Fee Related JP3986481B2 (ja) 1993-11-30 2003-09-11 シャペロニン１０

Country Status (11)

Country Link
US (3) US6113899A (enExample)
EP (2) EP0731811B1 (enExample)
JP (3) JP3987104B2 (enExample)
AT (1) ATE282634T1 (enExample)
AU (2) AU684578B2 (enExample)
CA (1) CA2177179C (enExample)
DE (1) DE69434137T2 (enExample)
ES (1) ES2233938T3 (enExample)
NZ (2) NZ276670A (enExample)
PT (1) PT731811E (enExample)
WO (2) WO1995015338A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015338A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Chaperonin 10
JP2001509396A (ja) * 1997-07-10 2001-07-24 メディカル リサーチ カウンシル シャペロン断片
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
AU2002317013B2 (en) * 2001-06-27 2007-11-01 Janssen Pharmaceutica N.V. EPF receptor assays, compounds and therapeutic compositions
AU2002952492A0 (en) * 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
JP2007517808A (ja) 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
EP2463307A1 (en) 2005-08-31 2012-06-13 CBIO Limited Modified chaperonin 10
CA2626692A1 (en) * 2005-10-20 2007-04-26 Cbio Limited Treatment of hypersensitivity
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
MX2008011167A (es) 2006-03-02 2008-11-12 Cbio Ltd Regulaciòn de respuestas inmunes mediante la modulaciòn de la funciòn de cèlulas presentadoras de antìgenos.
CA2720617A1 (en) 2008-04-11 2009-10-15 Cbio Limited Modified cpn10 and prr signalling
NZ599666A (en) * 2009-10-09 2014-11-28 Cbio Ltd Chaperonin 10 variants
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
KR101776013B1 (ko) * 2017-05-26 2017-09-07 (주)넥스젠바이오텍 항산화 활성 및 피부 세포 증식 효과가 증가한 열 충격 단백질 10과 브라제인 단백질의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU599021B2 (en) * 1985-03-12 1990-07-12 University Of Queensland, The Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody
EP0262119A1 (en) * 1985-03-12 1988-04-06 University Of Queensland Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody
EP0345260A4 (en) * 1986-12-22 1990-05-14 Univ Queensland METHOD FOR TREATING MAMMALS USING EARLY PREGNANCY FACTOR (EPF) ANTIBODIES.
AU1086988A (en) * 1986-12-22 1988-07-15 University Of Queensland, The Method of treatment of mammals using antibodies to early pregnancy factor (epf)
WO1995015338A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Chaperonin 10

Also Published As

Publication number Publication date
WO1995015339A1 (en) 1995-06-08
AU684577B2 (en) 1997-12-18
EP0731811A1 (en) 1996-09-18
AU1103495A (en) 1995-06-19
NZ276672A (en) 1998-01-26
EP0733071A4 (en) 1997-02-26
JPH09506431A (ja) 1997-06-24
EP0733071A1 (en) 1996-09-25
US7358329B2 (en) 2008-04-15
DE69434137T2 (de) 2005-12-01
JP3986481B2 (ja) 2007-10-03
CA2177179C (en) 2006-10-17
US6113899A (en) 2000-09-05
AU1103695A (en) 1995-06-19
ATE282634T1 (de) 2004-12-15
JPH09505811A (ja) 1997-06-10
US6417334B1 (en) 2002-07-09
EP0731811B1 (en) 2004-11-17
PT731811E (pt) 2005-04-29
DE69434137D1 (en) 2004-12-23
NZ276670A (en) 1998-01-26
US20030175280A1 (en) 2003-09-18
EP0731811A4 (en) 2003-05-28
WO1995015338A1 (en) 1995-06-08
JP2004067698A (ja) 2004-03-04
JP3545408B2 (ja) 2004-07-21
AU684578B2 (en) 1997-12-18
ES2233938T3 (es) 2005-06-16
CA2177179A1 (en) 1995-06-08

Similar Documents

Publication Publication Date Title
US7358329B2 (en) Antagonists to chaperonin 10
Goyert et al. Isolation of I–A subregion-like molecules from subhuman primates and man
Husby et al. Amyloid fibril protein subunit,‘protein AS’: distribution in tissue and serum in different clinical types of amyloidosis including that associated with myelomatosis and Waldenström's macroglobulinaemia
US5731167A (en) Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
IBRAHIM et al. Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis
Koshland et al. Differences in amino acid composition related to allotypic and antibody specificity of rabbit IgG heavy chains
CA2176948C (en) Chaperonin 10
JP2718827B2 (ja) 分泌Ｍａｃ−２結合糖タンパク質
CZ6997A3 (en) Proteins, extractable from mammal livers
US5434247A (en) Peptides for inducing monocyte cytotoxicity in diagnostics
JPH04505614A (ja) タンパク質複合体
JP2000515001A (ja) ダウンレギュレーション耐性ｃ３コンバターゼ
JPH03504248A (ja) 外来抗原に対する寛容の誘発
Teuscher et al. Experimental allergic orchitis: the isolation and partial characterization of an aspermatogenic polypeptide (AP3) with an apparent sequential disease-inducing determinant (s).
US7939635B2 (en) Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
EP0515494A1 (en) Use of inhibitor of cytokine activity
US6387875B1 (en) Method of use for murine leukaemia inhibitory factor-binding protein (mLBP)
JPH03502446A (ja) 動物およびヒトのレクチン類の少なくとも一部分の配列を再現するアミノ酸配列，それを得る方法，およびその診断および治療への用途
Percy et al. Functional Differentiation of B Lymphocytes in Congenital Agammaglobulinemia: II. Immunochemical Analysis of the in Vitro Primary Immune Response
WO1993016715A1 (en) Fsf-1 and the early detection of fibrosis
JP2608023B2 (ja) インターロイキン−１β誘導体及び医薬
MAIRE et al. FUNCTIONAL DIFFERENTIATION OF B LYMPHOCYTES IN CONGENITAL AGAMMAGLOBULINEMIA
JPH08253422A (ja) インターロイキン−１β誘導体及び医薬
JPH08225596A (ja) インターロイキン−１β誘導体及び医薬

Legal Events

Date Code Title Description
A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070712

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100720

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100720

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110720

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110720

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120720

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees